↓ Skip to main content

Dove Medical Press

Article Metrics

Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial

Overview of attention for article published in Neuropsychiatric Disease and Treatment, May 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
2 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
58 Mendeley
Title
Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial
Published in
Neuropsychiatric Disease and Treatment, May 2015
DOI 10.2147/ndt.s85711
Pubmed ID
Authors

Yan He, Ruiying Kang, Yuxiang Yan, Zhiwu Li, Yeqing Wu, Xiaojuan Guo, Zhigang Liang, Jun Jiang

Abstract

Comorbid depression/anxiety in type 2 diabetes mellitus (DM) patients is highly prevalent, affecting both diabetes control and quality of life. However, the best treating method for depression/anxiety in type 2 DM patients is still unclear. This study was conducted to compare the efficacy of paroxetine and agomelatine on depression/anxiety and metabolic control of type 2 DM patients. A total of 116 depressed, type 2 DM patients were recruited for 12 weeks treatment. Patients were randomly assigned to receive either paroxetine or agomelatine. Hamilton Depression Rating Scale and Hamilton Anxiety Rating Scale were used to assess depression and anxiety, respectively. Hemoglobin A1c, fasting plasma glucose, and body mass index were assessed at baseline and at the end of the trial. At the end of the trial, there were 34 (60.7%) responders and 22 (39.3%) remissions in paroxetine group; and 38 (63.3%) responders and 26 (43.3%) remissions in agomelatine group. Compared to paroxetine group, lower depression scores were observed in agomelatine group. Fasting plasma glucose and body mass index were not significantly different after 12 weeks treatment between the two groups, but agomelatine group had a significantly lower final hemoglobin A1c level compared to paroxetine group. The two antidepressants had comparable acceptability. These results showed that compared to paroxetine, agomelatine might have some advantages in treating symptoms of depression/anxiety and glycemic control in depressed type 2 DM patients. The clinical applicability of agomelatine shows greater promise and should be explored further. Limited by the relatively small samples, future studies are needed to verify and support our findings.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 58 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 58 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 13 22%
Student > Ph. D. Student 8 14%
Researcher 7 12%
Student > Bachelor 5 9%
Student > Postgraduate 4 7%
Other 8 14%
Unknown 13 22%
Readers by discipline Count As %
Medicine and Dentistry 18 31%
Psychology 8 14%
Nursing and Health Professions 4 7%
Biochemistry, Genetics and Molecular Biology 2 3%
Social Sciences 2 3%
Other 7 12%
Unknown 17 29%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 May 2015.
All research outputs
#8,769,267
of 14,535,828 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,294
of 2,442 outputs
Outputs of similar age
#115,986
of 235,581 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#42
of 52 outputs
Altmetric has tracked 14,535,828 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,442 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one is in the 39th percentile – i.e., 39% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 235,581 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 52 others from the same source and published within six weeks on either side of this one. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.